LT3773589T - Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui - Google Patents
Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimuiInfo
- Publication number
- LT3773589T LT3773589T LTEPPCT/US2019/025655T LTUS2019025655T LT3773589T LT 3773589 T LT3773589 T LT 3773589T LT US2019025655 T LTUS2019025655 T LT US2019025655T LT 3773589 T LT3773589 T LT 3773589T
- Authority
- LT
- Lithuania
- Prior art keywords
- ret
- treating cancer
- alteration
- inhibitor
- ret inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000004075 alteration Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862652284P | 2018-04-03 | 2018-04-03 | |
US201862656297P | 2018-04-11 | 2018-04-11 | |
US201862657605P | 2018-04-13 | 2018-04-13 | |
US201862741683P | 2018-10-05 | 2018-10-05 | |
PCT/US2019/025655 WO2019195471A1 (en) | 2018-04-03 | 2019-04-03 | Ret inhibitor for use in treating cancer having a ret alteration |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3773589T true LT3773589T (lt) | 2024-02-12 |
Family
ID=66223846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2019/025655T LT3773589T (lt) | 2018-04-03 | 2019-04-03 | Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui |
Country Status (24)
Country | Link |
---|---|
US (4) | US20210100795A1 (lt) |
EP (2) | EP4353317A3 (lt) |
JP (3) | JP7422084B2 (lt) |
KR (1) | KR20200139749A (lt) |
AU (1) | AU2019247766A1 (lt) |
BR (1) | BR112020020273A2 (lt) |
CA (1) | CA3096043A1 (lt) |
CL (1) | CL2020002544A1 (lt) |
CR (1) | CR20200522A (lt) |
DK (1) | DK3773589T3 (lt) |
ES (1) | ES2970041T3 (lt) |
FI (1) | FI3773589T3 (lt) |
HR (1) | HRP20240124T1 (lt) |
IL (1) | IL277629A (lt) |
LT (1) | LT3773589T (lt) |
MX (1) | MX2020010417A (lt) |
PE (1) | PE20210096A1 (lt) |
PL (1) | PL3773589T3 (lt) |
PT (1) | PT3773589T (lt) |
RS (1) | RS65127B1 (lt) |
SG (1) | SG11202009681YA (lt) |
SI (1) | SI3773589T1 (lt) |
WO (1) | WO2019195471A1 (lt) |
ZA (1) | ZA202006072B (lt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
FI3371171T3 (fi) | 2015-11-02 | 2024-01-10 | Blueprint Medicines Corp | Ret:n estäjiä |
US20210100795A1 (en) | 2018-04-03 | 2021-04-08 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
US11666570B2 (en) * | 2019-07-11 | 2023-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnosis and regulation of epidermal differentiation and cancer cell activity |
US11946935B2 (en) * | 2020-08-25 | 2024-04-02 | Regents Of The University Of Minnesota | Circulating tumor markers for meningiomas |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1429222A (zh) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
CA2493000A1 (en) | 2002-07-24 | 2004-01-29 | University Of Cincinnati | 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
WO2005062795A2 (en) | 2003-12-19 | 2005-07-14 | Plexxikon, Inc. | Compounds and methods for development of ret modulators |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
AU2006244203B2 (en) | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
WO2006128042A2 (en) | 2005-05-26 | 2006-11-30 | The Johns Hopkins University | Methods of identifying mutations in nucleic acid |
WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
WO2007087245A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Ret tyrosine kinase inhibition |
ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
WO2008061201A1 (en) | 2006-11-15 | 2008-05-22 | Rigel Pharmaceuticals, Inc. | Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds |
US20090012045A1 (en) | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
CA2693967A1 (en) | 2007-07-19 | 2009-01-29 | Schering Corporation | Heterocyclic amide compounds as protein kinase inhibitors |
WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
CA2730190A1 (en) | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
AU2010229140A1 (en) | 2009-03-24 | 2011-11-10 | Msd K.K. | Novel aminopyridine derivatives having Aurora A selective inhibitory action |
CN102573483A (zh) | 2009-06-08 | 2012-07-11 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
WO2010144394A1 (en) | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Benzyl substituted triazine derivatives and their therapeutical applications |
WO2011053938A1 (en) | 2009-10-30 | 2011-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for treating cancer |
US8629132B2 (en) | 2009-11-13 | 2014-01-14 | Genosco | Kinase inhibitors |
EP2740742B1 (en) | 2011-08-04 | 2018-03-14 | National Cancer Center | Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene |
EP3564261A1 (en) | 2011-08-23 | 2019-11-06 | Foundation Medicine, Inc. | Kif5b-ret fusion molecules and uses thereof |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
US20130096136A1 (en) | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
US10023855B2 (en) | 2011-10-31 | 2018-07-17 | Macrogen, Inc. | Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
KR20140131955A (ko) | 2012-03-09 | 2014-11-14 | 카나 바이오사이언스 인코포레이션 | 신규 트리아진 유도체 |
JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ret融合体の検出法 |
RU2646754C2 (ru) | 2012-04-25 | 2018-03-07 | Раквалиа Фарма Инк. | Производные пирролопиридинона в качестве ttx-s блокаторов |
WO2013170159A1 (en) | 2012-05-10 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
ES2916220T3 (es) | 2012-07-11 | 2022-06-29 | Blueprint Medicines Corp | Inhibidores del receptor de factor de crecimiento de fibroblasto |
WO2014017491A1 (ja) | 2012-07-26 | 2014-01-30 | 独立行政法人国立がん研究センター | Cep55遺伝子とret遺伝子との融合遺伝子 |
CN104703600A (zh) | 2012-09-07 | 2015-06-10 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
JP5759568B2 (ja) | 2012-09-25 | 2015-08-05 | 中外製薬株式会社 | Ret阻害剤 |
US9604980B2 (en) | 2012-11-07 | 2017-03-28 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors |
TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
CN105102468A (zh) | 2013-02-25 | 2015-11-25 | 百时美施贵宝公司 | 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物 |
AU2014229233B2 (en) | 2013-03-15 | 2016-08-11 | Glaxosmithkline Intellectual Property Development Limited | Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors |
EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
WO2014147640A2 (en) | 2013-03-19 | 2014-09-25 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for the preparation of anagliptin |
WO2015006875A1 (en) | 2013-07-18 | 2015-01-22 | Methylgene Inc. | Process for the preparation of substituted pyrimidines |
US20150057335A1 (en) | 2013-08-20 | 2015-02-26 | National Cancer Center | Novel fusion genes identified in lung cancer |
DK3057969T3 (en) | 2013-10-17 | 2018-09-24 | Blueprint Medicines Corp | COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT |
WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
ES2924111T3 (es) | 2013-10-25 | 2022-10-04 | Blueprint Medicines Corp | Inhibidores del receptor del factor de crecimiento de fibroblastos |
GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
SG11201701694QA (en) | 2014-09-10 | 2017-04-27 | Glaxosmithkline Ip Dev Ltd | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
CR20170094A (es) | 2014-09-10 | 2017-05-08 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) |
MX2017006366A (es) | 2014-11-14 | 2018-02-01 | Nerviano Medical Sciences Srl | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa. |
US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
CN104844567B (zh) | 2015-04-23 | 2017-03-29 | 暨南大学 | 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法 |
AU2016291676B2 (en) | 2015-07-16 | 2020-04-30 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
EP3325481B1 (en) | 2015-07-24 | 2019-06-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
CN108137607B (zh) | 2015-08-26 | 2021-04-06 | 缆图药品公司 | 适用于治疗与ntrk相关的病症的化合物和组合物 |
CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
FI3371171T3 (fi) | 2015-11-02 | 2024-01-10 | Blueprint Medicines Corp | Ret:n estäjiä |
KR20180069903A (ko) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
US20170121420A1 (en) | 2015-11-02 | 2017-05-04 | Janssen Pharmaceutica Nv | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof |
SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
CN108602890A (zh) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 |
WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
EP3436018A4 (en) | 2016-04-01 | 2019-11-13 | Signal Pharmaceuticals, LLC | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF |
SG10201911665UA (en) | 2016-04-15 | 2020-01-30 | Cancer Research Tech Ltd | Heterocyclic compounds as ret kinase inhibitors |
ES2925698T3 (es) | 2016-04-15 | 2022-10-19 | Cancer Research Tech Ltd | Compuestos heterocíclicos como inhibidores de la quinasa RET |
CN109311889B (zh) | 2016-04-15 | 2021-11-16 | 缆图药品公司 | 激活素受体样激酶抑制剂 |
US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
JP2018052878A (ja) | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
CN106749231B (zh) | 2016-10-09 | 2019-03-01 | 南京纳丁菲医药科技有限公司 | 萘啶化合物和药物组合物及它们的应用 |
TWI704148B (zh) * | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
WO2018102455A1 (en) | 2016-12-01 | 2018-06-07 | Ignyta, Inc. | Methods for the treatment of cancer |
JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物 |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
US20210290620A1 (en) * | 2017-05-15 | 2021-09-23 | Blueprint Medicines Corporation | Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity |
WO2018237134A1 (en) | 2017-06-23 | 2018-12-27 | San Diego State University Research Foundation | ATROPISOMERISM FOR ENHANCED SELECTIVITY OF KINASE INHIBITORS |
CN109180677A (zh) | 2017-06-30 | 2019-01-11 | 厦门大学 | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 |
CA3068122A1 (en) | 2017-07-07 | 2019-01-10 | Nipd Genetics Public Company Limited | Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers |
CN107980784B (zh) | 2017-12-13 | 2020-05-26 | 中国农业大学 | 5-氨基吡唑类化合物在调节植物生长方面的应用 |
CN111511746B (zh) | 2017-12-19 | 2024-01-09 | 特普医药公司 | 用于治疗疾病的巨环化合物 |
US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
CN108341782A (zh) | 2018-03-30 | 2018-07-31 | 南京哈柏医药科技有限公司 | 3-氨基-5-甲基吡唑的合成工艺 |
US20210100795A1 (en) | 2018-04-03 | 2021-04-08 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
US20210308134A1 (en) | 2018-08-10 | 2021-10-07 | Blueprint Medicines Corporation | Treatment of egfr-mutant cancer |
CN111440151A (zh) | 2020-03-25 | 2020-07-24 | 魏威 | 制备抗肿瘤药普拉赛替尼的方法 |
CN111362923A (zh) | 2020-03-25 | 2020-07-03 | 魏威 | 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法 |
AU2021281283A1 (en) | 2020-05-29 | 2022-12-15 | Blueprint Medicines Corporation | Pralsetinib pharmaceutical compositions |
US20230295121A1 (en) | 2020-05-29 | 2023-09-21 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
TW202237567A (zh) | 2020-12-04 | 2022-10-01 | 美商纜圖藥品公司 | 製備普拉替尼(pralsetinib)之方法 |
-
2019
- 2019-04-03 US US17/044,884 patent/US20210100795A1/en active Pending
- 2019-04-03 SI SI201930702T patent/SI3773589T1/sl unknown
- 2019-04-03 PL PL19718531.7T patent/PL3773589T3/pl unknown
- 2019-04-03 CR CR20200522A patent/CR20200522A/es unknown
- 2019-04-03 FI FIEP19718531.7T patent/FI3773589T3/fi active
- 2019-04-03 HR HRP20240124TT patent/HRP20240124T1/hr unknown
- 2019-04-03 WO PCT/US2019/025655 patent/WO2019195471A1/en active Application Filing
- 2019-04-03 ES ES19718531T patent/ES2970041T3/es active Active
- 2019-04-03 MX MX2020010417A patent/MX2020010417A/es unknown
- 2019-04-03 EP EP23199171.2A patent/EP4353317A3/en active Pending
- 2019-04-03 PE PE2020001523A patent/PE20210096A1/es unknown
- 2019-04-03 EP EP19718531.7A patent/EP3773589B1/en active Active
- 2019-04-03 LT LTEPPCT/US2019/025655T patent/LT3773589T/lt unknown
- 2019-04-03 RS RS20240107A patent/RS65127B1/sr unknown
- 2019-04-03 PT PT197185317T patent/PT3773589T/pt unknown
- 2019-04-03 CA CA3096043A patent/CA3096043A1/en active Pending
- 2019-04-03 AU AU2019247766A patent/AU2019247766A1/en active Pending
- 2019-04-03 DK DK19718531.7T patent/DK3773589T3/da active
- 2019-04-03 BR BR112020020273-8A patent/BR112020020273A2/pt unknown
- 2019-04-03 JP JP2020553633A patent/JP7422084B2/ja active Active
- 2019-04-03 SG SG11202009681YA patent/SG11202009681YA/en unknown
- 2019-04-03 KR KR1020207031426A patent/KR20200139749A/ko unknown
-
2020
- 2020-09-27 IL IL277629A patent/IL277629A/en unknown
- 2020-09-30 ZA ZA2020/06072A patent/ZA202006072B/en unknown
- 2020-10-01 CL CL2020002544A patent/CL2020002544A1/es unknown
- 2020-10-02 US US17/061,743 patent/US11963958B2/en active Active
- 2020-12-18 US US17/127,041 patent/US11273160B2/en active Active
-
2021
- 2021-07-16 US US17/377,885 patent/US11872192B2/en active Active
- 2021-12-09 JP JP2021199945A patent/JP2022022391A/ja active Pending
-
2023
- 2023-09-28 JP JP2023167564A patent/JP2023165937A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277783A (en) | SHP2 inhibitory compositions, methods for treating cancer and methods for identifying a subject with SHP2 mutations | |
IL277629A (en) | RET inhibitor for use in the treatment of cancer involving a change in RET | |
FI3704108T3 (fi) | Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon | |
IL282663A (en) | BT1718 for use in cancer treatment | |
IL284199A (en) | CSF1R inhibitors for cancer treatment | |
SI3371165T1 (sl) | Zaviralec BTK za uporabo pri zdravljenju raka | |
IL259479B (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
SG11202112452WA (en) | Methods for treating cancer | |
GB201820660D0 (en) | Cancer treatments | |
IL284856A (en) | DBAIT molecule in combination with a kinase inhibitor for cancer treatment | |
SG11202010528XA (en) | Combinations for treating cancer | |
EP3966208A4 (en) | COMPOUNDS AND METHODS FOR TREATING CANCER | |
ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
SG11202108745RA (en) | Combination therapies for use in treating cancer | |
PT3813832T (pt) | Compostos para utilização na prevenção ou tratamento de cancro | |
GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
GB201807415D0 (en) | Cancer treatments | |
GB201802264D0 (en) | Cancer treatments |